【摘要】 目的　探讨口服华法令抗凝患者血浆蛋白C (PC)、蛋白S (PS)活性的改变及其临床意义。方法　用凝固法在SysmexCA 15 0 0、CA 60 0 0全自动血凝仪上检测 30例口服华法令抗凝的心脏瓣膜置换患者和 40例正常对照者的血浆PC、PS活性和凝血酶原时间 (PT)。结果　口服华法令抗凝患者血浆PT ,INR ,PC ,PS活性分别为 ( 2 5 5± 5 3)s ,2 5± 0 5 ,( 39 2± 15 1) % ,( 45 7± 18 2 ) % ,与对照组比较 ,差异均有极显著性意义 (P均 <0 0 1)。结论　口服华法令抗凝患者血浆PC ,PS活性降低 ,华法令的抗凝效果受到一定程度的减弱更多还原

【Abstract】 Objective To study the change of activity of plasm a protein C (PC) and protein S (PS) in patients treated with warfarin. Methods Clotting assays on Sysmex CA 1500 and CA 6000 autoanalyzer were used to detect the activity of pl asma PC, PS and PT in 30 patients treated with warfarin and 40 normal controls (NC). Results PT,INR and the activity of plasma PC and PS in patients group wer e (25.5±5.3)s,2.5±0.5,(39.2±15.1)%,(45.7±18.2)%, respectively. Th ere was significant difference between patients group and NC group (P<0.01). Conclusion The activity of plasma PC and PS in patients tr eated with warfarin decreases, which reduces the anticoagulant effect of warfari n.更多还原